Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells

被引:37
作者
Ryan, Elizabeth P.
Pollock, Stephen J.
Kaur, Kuljeet
Felgar, Raymond E.
Bernstein, Steven H.
Chiorazzi, Nicholas
Phipps, Richard P.
机构
[1] Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA
[2] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA
[3] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA
[4] Univ Rochester, Sch Med & Dent, James P Wilmot Canc Ctr, Rochester, NY 14642 USA
[5] N Shore LIJ Hlth Syst, Med Res Inst, Manhasset, NY 11030 USA
关键词
cyclooxygenase-2; prostaglandins; B-Chronic Lymphocytic Leukemia (B-CLL); NSAIDs and Cox-2 selective inhibitors;
D O I
10.1016/j.clim.2005.12.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We recently reported that activated normal human B lymphocytes express Cox-2. These findings prompted us to evaluate whether human B-CLL cells express Cox-2 and synthesize prostaglandins. In contrast to naive human B cells, B-CLL cells constitutively expressed Cox-2 protein and produced PGE(2), PGF(2 alpha), and TXA(2). Elevated Cox-2 expression was seen in a subgroup of B-CLL cells that exhibit poor prognostic factors, including unmutated variable heavy chain status and increased CD38 expression. Furthermore, stimulation of B-CLL cells with CD40 ligand plus TNF alpha increased Cox-2 levels. The role of Cox-2 in promoting B-CLL survival was investigated using nonselective and selective Cox-2 inhibitors. Significant reductions in B-CLL survival occurred following Cox-2 inhibition. These new findings support that constitutive Cox-2 expression in B-CLL cells promotes their survival and possibly their expansion in vivo. It will therefore be important to evaluate drugs that inhibit Cox-2 as potential therapeutic agents in B-CLL in vivo. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:76 / 90
页数:15
相关论文
共 51 条
[1]  
ARMSTRONG RA, 1991, ADV PROSTAG THROMB L, V21, P375
[2]   The role of COX-2 inhibition in breast cancer treatment and prevention [J].
Arun, B ;
Goss, P .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :22-29
[3]   Update on the biology of chronic lymphocytic leukemia [J].
Bannerji, R ;
Byrd, JC .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (01) :22-29
[4]   Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells [J].
Bellosillo, B ;
Piqué, M ;
Barragán, M ;
Castaño, E ;
Villamor, N ;
Colomer, D ;
Montserrat, E ;
Pons, G ;
Gil, J .
BLOOD, 1998, 92 (04) :1406-1414
[5]   The MET oncogene drives a genetic programme linking cancer to haemostasis [J].
Boccaccio, C ;
Sabatino, G ;
Medico, E ;
Girolami, F ;
Follenzi, A ;
Reato, G ;
Sottile, A ;
Naldini, L ;
Comoglio, PM .
NATURE, 2005, 434 (7031) :396-400
[6]   Cyclooxygenase as a target in lung cancer [J].
Brown, JR ;
DuBois, RN .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4266S-4269S
[7]  
Capone ML, 2003, INT J IMMUNOPATH PH, V16, P49
[8]   Mechanisms of disease: Chronic lymphocytic leukemia [J].
Chiorazzi, N ;
Rai, KR ;
Ferrarini, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :804-815
[9]   A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells [J].
Cuní, S ;
Pérez-Aciego, P ;
Pérez-Chacón, G ;
Vargas, JA ;
Sánchez, A ;
Martín-Saavedra, FM ;
Ballester, S ;
García-Marco, J ;
Jordá, J ;
Durántez, A .
LEUKEMIA, 2004, 18 (08) :1391-1400
[10]   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].
Damle, RN ;
Wasil, T ;
Fais, F ;
Ghiotto, F ;
Valetto, A ;
Allen, SL ;
Buchbinder, A ;
Budman, D ;
Dittmar, K ;
Kolitz, J ;
Lichtman, SM ;
Schulman, P ;
Vinciguerra, VP ;
Rai, KR ;
Ferrarini, M ;
Chiorazzi, N .
BLOOD, 1999, 94 (06) :1840-1847